GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vaxart Inc (STU:NB11) » Definitions » Cyclically Adjusted Price-to-FCF

Vaxart (STU:NB11) Cyclically Adjusted Price-to-FCF : (As of Jun. 05, 2025)


View and export this data going back to . Start your Free Trial

What is Vaxart Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Vaxart Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Vaxart's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vaxart Cyclically Adjusted Price-to-FCF Chart

Vaxart Annual Data
Trend Jun15 Jun16 Jun17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Vaxart Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Vaxart's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Vaxart's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vaxart's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vaxart's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Vaxart's Cyclically Adjusted Price-to-FCF falls into.


;
;

Vaxart Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Vaxart's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, Vaxart's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2025 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=-0.039/134.9266*134.9266
=-0.039

Current CPI (Mar. 2025) = 134.9266.

Vaxart Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201506 0.054 100.684 0.072
201509 0.228 100.392 0.306
201512 -2.379 99.792 -3.217
201603 -1.789 100.470 -2.403
201606 0.253 101.688 0.336
201609 -2.714 101.861 -3.595
201612 -2.429 101.863 -3.217
201703 -3.061 102.862 -4.015
201706 0.304 103.349 0.397
201709 -1.075 104.136 -1.393
201712 -1.130 104.011 -1.466
201803 -1.642 105.290 -2.104
201806 0.827 106.317 1.050
201809 -0.664 106.507 -0.841
201812 -0.725 105.998 -0.923
201903 -0.631 107.251 -0.794
201906 -0.029 108.070 -0.036
201909 -0.249 108.329 -0.310
201912 -0.071 108.420 -0.088
202003 -0.048 108.902 -0.059
202006 -0.006 108.767 -0.007
202009 -0.075 109.815 -0.092
202012 -0.087 109.897 -0.107
202103 -0.125 111.754 -0.151
202106 -0.105 114.631 -0.124
202109 -0.107 115.734 -0.125
202112 -0.119 117.630 -0.136
202203 -0.191 121.301 -0.212
202206 -0.211 125.017 -0.228
202209 -0.173 125.227 -0.186
202212 -0.201 125.222 -0.217
202303 -0.178 127.348 -0.189
202306 -0.119 128.729 -0.125
202309 -0.094 129.860 -0.098
202312 -0.087 129.419 -0.091
202403 -0.116 131.776 -0.119
202406 -0.062 132.554 -0.063
202409 -0.017 133.029 -0.017
202412 -0.031 133.157 -0.031
202503 -0.039 134.927 -0.039

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Vaxart  (STU:NB11) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Vaxart Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Vaxart's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Vaxart Business Description

Industry
Traded in Other Exchanges
Address
170 Harbor Way, Suite 300, South San Francisco, CA, USA, 94080
Vaxart Inc is a clinical-stage biotechnology company. It focuses on the development of oral recombinant vaccines based on its Vector Adjuvant Antigen Standardized Technology to protect against a wide range of infectious diseases. The products under its tablet pipeline consist of the treatment of Coronavirus, Norovirus, Seasonal Influenza, RSV(respiratory syncytial virus), and HPV(Human papillomavirus) Therapeutic. It operates in a single segment, which is the discovery and development of oral recombinant protein vaccines. Geographically all the business activity functions through the region of the United States.

Vaxart Headlines

No Headlines